How to Apply to Guardant Health

Key Takeaways

Guardant Health is a NASDAQ-listed (GH), commercial-stage precision oncology company headquartered in Palo Alto, California, with additional Bay Area operations in Redwood City, a Washington, D.C. presence, and an international footprint anchored by a Japan subsidiary. Approximately 1,500 employees globally.
Co-founders Helmy Eltoukhy, PhD and AmirAli Talasaz, PhD have served as co-Chief Executive Officers and co-Chairs since founding the company in 2012. The dual-CEO structure has been deliberately maintained as the company has scaled, and is a real cultural feature candidates should understand.
Three commercial product franchises: Guardant360 (FDA-approved companion diagnostic for therapy selection in advanced solid tumors), Reveal (tumor-naive, methylation-based MRD assay), and Shield (FDA-approved July 2024, the first blood-based test for colorectal cancer screening in average-risk adults — a transformative ~$1B+ market opportunity).
The applicant tracking system is SmartRecruiters, hosted at careers.smartrecruiters.com/GuardantHealth (case-sensitive identifier).
Hiring is concentrated in Shield commercial sales (substantial 2024-2025 expansion for the primary-care call point), oncology specialty sales for Guardant360 and Reveal, R&D and computational biology, CLIA laboratory operations, regulatory affairs, medical affairs, software engineering, and corporate functions.
Competitive context is intense and well-funded: Natera (Signatera) in MRD, Exact Sciences (Cologuard, Cologuard Plus) in colorectal screening, Foundation Medicine (Roche) and others in genomic profiling. Pay is competitive with Bay Area biotech peers.
Interview loops are typically 4 to 6 rounds, scientifically deep for R&D, regulated-lab-pragmatic for laboratory operations, and oncology-customer-savvy for commercial. Expect a technical, scientific, or case-based exercise in addition to behavioral interviews.
Compensation includes base salary, target bonus or sales incentive, RSU equity, and benefits. Negotiation is expected, particularly on equity and sign-on for candidates leaving competing offers.

About Guardant Health

Guardant Health, Inc. (NASDAQ: GH) is a precision oncology company headquartered in Palo Alto, California, that develops and commercializes blood-based genomic tests intended to change how cancer is detected, treated, and monitored. The company was founded in 2012 by Helmy Eltoukhy, PhD, and AmirAli Talasaz, PhD — both Stanford-trained engineers who came out of the early next-generation sequencing world (Eltoukhy as a co-founder of Avantome, which Illumina acquired in 2008) — and the two remain co-Chief Executive Officers and co-Chairs of the Board to this day. The dual-CEO structure, unusual at scale, has been deliberately maintained as Guardant has grown from a venture-backed startup into a publicly traded commercial-stage diagnostics company with roughly 1,500 employees, multiple FDA-approved products, and operations spanning a Bay Area corporate and laboratory footprint, an East Coast clinical and government-affairs presence in Washington, D.C., and a growing international footprint with subsidiaries in Japan and elsewhere. The company's strategy rests on the premise that liquid biopsy — the ability to detect tumor-derived DNA, RNA, methylation patterns, and other biomarkers from a routine blood draw — can compete with, and in important settings replace, invasive tissue biopsy and existing screening modalities. That premise has produced three commercially distinct franchises that map cleanly onto cancer's three major clinical battlegrounds: advanced disease, post-treatment monitoring, and population screening. Guardant360, the flagship therapy-selection assay, was the first product to scale. It is a comprehensive genomic profiling test that uses cell-free DNA from blood to identify clinically actionable alterations in patients with advanced solid tumors, helping oncologists pick targeted therapies and immunotherapy regimens. Guardant360 received FDA approval as a companion diagnostic in 2020 — the agency's first liquid biopsy approval covering multiple solid tumor types — and has been used in well over half a million patient tests cumulatively. It remains the revenue base on which everything else at Guardant has been built. Reveal is the company's molecular residual disease (MRD) assay, addressing one of the highest-stakes questions in oncology: after surgery or definitive treatment, is there still cancer present at a molecular level that imaging cannot yet see? Reveal is a tumor-naive, methylation-based MRD test that does not require sequencing the patient's resected tumor first, a workflow that is materially simpler for oncology practices than competing tumor-informed approaches. The product is being deployed in colorectal, breast, and other solid tumor settings, and the underlying clinical evidence pipeline (trials, registry studies, and reimbursement submissions) remains a major area of investment. Shield is the most consequential and most-watched product in the portfolio. It is a blood-based test for colorectal cancer screening in average-risk adults age 45 and older — the first such blood test ever to receive FDA premarket approval, granted in July 2024. Shield is positioned to compete in a multibillion-dollar U.S. screening market currently dominated by colonoscopy and stool-based tests (most prominently Exact Sciences' Cologuard). The strategic logic is straightforward: roughly one-third of eligible Americans are not up to date on colorectal cancer screening, and a blood draw at a primary-care visit is operationally easier than scheduling a colonoscopy or completing an at-home stool test. Medicare national coverage determination, commercial payer coverage, and a substantial sales-force build-out in 2024 and 2025 have made Shield the single largest commercial mobilization in the company's history. Guardant's competitive landscape is intense and well-funded. Natera, Inc. (NASDAQ: NTRA) is the principal MRD competitor through its Signatera assay and competes head-to-head with Reveal across multiple tumor types. Exact Sciences (NASDAQ: EXAS) is the dominant incumbent in colorectal screening through Cologuard and is developing its own next-generation blood test (Cologuard Plus), making the Shield versus Cologuard battle a defining commercial story for the second half of the 2020s. Foundation Medicine (a Roche subsidiary) competes with Guardant360 in tissue and liquid genomic profiling, and Veracyte, Caris Life Sciences, Tempus AI, and a long tail of academic and startup competitors round out the market. Guardant's response is to lean on scale, the breadth of its biopharma data partnerships, and the integration of its three product lines into a single end-to-end oncology data platform — from screening (Shield) to therapy selection (Guardant360) to monitoring (Reveal). The company is publicly traded on NASDAQ under the ticker GH, having gone public in October 2018. SoftBank made a substantial early investment via its Vision Fund and remains a meaningful shareholder. Revenue mix is heavily oncology-services-led (clinical testing reimbursed primarily through Medicare, commercial payers, and patient self-pay), supplemented by biopharmaceutical research-services revenue from drug-development partnerships, and increasingly by Shield screening volumes as commercial adoption ramps. The company is not yet GAAP-profitable on a sustained basis — investments in Shield commercialization, MRD trials, and clinical evidence generation are sizeable — and free cash flow is a closely watched metric on quarterly earnings calls. For a job seeker, what makes Guardant distinctive is the combination of a deeply technical scientific culture (genomics, bioinformatics, machine learning, CLIA/CAP laboratory operations) with a fast-scaling commercial organization (oncology sales, primary-care sales for Shield, market access, payer relations) operating against a small set of well-resourced competitors in a regulated diagnostics market. People who join Guardant are joining a company where the science still matters every day, the lab is the product, and the commercial bet on Shield is large enough to materially reshape the company's revenue trajectory if it succeeds.

Application Process

1
Step 1
Step 1 — Find the role on Guardant Health's careers site at guardanthealth.com/careers, which routes to the company's SmartRecruiters-hosted job board at careers.smartrecruiters.com/GuardantHealth. Job postings are filterable by department (Research & Development, Clinical Operations, Commercial, Medical Affairs, Laboratory Operations, Bioinformatics & Software, Regulatory Affairs, Quality, Finance, IT/Engineering, Human Resources) and by location (Palo Alto CA, Redwood City CA, Washington DC, plus field-based sales territories nationwide and select international postings).
2
Step 2
Step 2 — Create a SmartRecruiters candidate profile. SmartRecruiters accepts a resume upload as PDF or .docx, parses it into structured fields (work history, education, skills), and pre-populates the application form. You will be asked to confirm or edit the parsed fields before submission, and to add a cover letter where the requisition supports it. Linking a LinkedIn profile is supported and can speed up the parsing step.
3
Step 3
Step 3 — Complete Guardant-specific custom questions. These commonly include U.S. work authorization (Guardant sponsors visas selectively, mostly for advanced scientific and software engineering roles where domestic supply is constrained), willingness to be on-site or hybrid in Palo Alto, Redwood City, or DC, salary expectations, source of referral, and one or two role-specific short-answer prompts (for example, 'describe your experience working in a CLIA-regulated laboratory environment' or 'what about precision oncology motivates you to join Guardant Health?').
4
Step 4
Step 4 — Submit and expect an initial recruiter response within 1 to 3 weeks. Guardant's talent acquisition function is in-house for most roles, with specialty agencies retained for senior commercial leadership, sales-force build-outs, and select hard-to-fill scientific positions. For high-volume Shield commercial sales territory roles in 2024-2025, response times have generally been faster than for senior R&D postings.
5
Step 5
Step 5 — Recruiter phone screen (30 minutes). The recruiter confirms logistics — compensation expectations, location, work authorization, notice period — walks through your background, and assesses culture fit. Expect questions about why precision oncology, what you know about Guardant360 versus Reveal versus Shield, and how you have navigated regulated environments (CLIA, CAP, FDA, HIPAA) if relevant to the role.
6
Step 6
Step 6 — Hiring manager interview (45 to 60 minutes). For technical and scientific roles, this is a deep dive into your domain expertise, recent project history, and reasoning. For commercial and sales roles, expect a structured discussion of your territory management, account-planning, and oncology customer-relationship experience. The hiring manager will also articulate the role's mandate, success measures for the first 6 to 12 months, and the team structure.
7
Step 7
Step 7 — Panel or loop interviews (typically 4 to 6 sessions, 30 to 60 minutes each). These can run as a single virtual or onsite loop or be scheduled across 1 to 3 weeks depending on the role's seniority. Panels include cross-functional partners — for example, an MSAT or process development role might meet QC, R&D, Regulatory, and Manufacturing leaders — at least one peer, and frequently a skip-level executive for director-and-above roles.
8
Step 8
Step 8 — Technical exercise, presentation, or case study where applicable. R&D and bioinformatics roles often include a 'present your past work' session where you walk a panel through a recent project and answer probing methods questions, or a journal-club-style discussion of a published paper relevant to the role. Software engineering interviews include a coding interview (commonly using SmartRecruiters' integrated assessment or a third-party platform such as CoderPad). Commercial roles often include a territory-plan or launch-readiness case based on a real Guardant scenario (Shield primary-care call patterns, Guardant360 oncology key-account strategy, MRD evidence-based selling in colorectal).
9
Step 9
Step 9 — References, background check, and offer. Guardant runs standard third-party background checks (criminal history, employment verification, education verification, and where role-relevant, professional license verification). Expect a written offer detailing base salary, target bonus or sales incentive plan, restricted stock unit (RSU) grant, sign-on bonus where applicable, relocation support, and benefits summary. Negotiation is expected; recruiters are accustomed to counter-offers, particularly on equity and sign-on for candidates leaving competing offers.
10
Step 10
Step 10 — Onboarding. New hires complete pre-employment paperwork through Workday or SmartRecruiters Onboard, followed by a structured orientation that covers Guardant's product portfolio, the regulatory framework around the lab and FDA-approved products, HIPAA and information-security training, and role-specific functional onboarding. CLIA laboratory hires complete site-specific GMP-equivalent training, gowning qualification (where applicable), and SOP read-and-understand sign-offs in the first 30 to 60 days. Field-based sales hires typically complete a multi-week launch academy combining product, clinical, payer, and selling-skills curricula.

Resume Tips for Guardant Health

recommended

Lead with precision oncology, liquid biopsy, and assay-development keywords if y

Lead with precision oncology, liquid biopsy, and assay-development keywords if you have them. Cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), next-generation sequencing (NGS), targeted panel design, hybrid capture, methylation, MRD (molecular residual disease), companion diagnostic (CDx), CLIA, CAP, ISO 15189, 21 CFR Part 820, FDA 510(k) and PMA, and IVD development are all terms Guardant recruiters and SmartRecruiters keyword filters look for. Adjacent experience in oncology drug development, NGS instrumentation, or clinical bioinformatics should be made unmistakably searchable in the resume body, not buried in a paragraph.

recommended

Quantify regulated-laboratory experience explicitly

Quantify regulated-laboratory experience explicitly. 'Authored 18 deviation investigations under CLIA-regulated NGS workflow' lands harder than 'experience with deviations.' For R&D applicants, cite assay performance metrics (limit of detection, sensitivity, specificity, positive predictive value, concordance with tissue). For clinical operations, name the protocol phase, indication, study size, and your specific role (for example, 'CRA on a 2,500-patient prospective MRD study in stage II/III colorectal cancer, 60+ U.S. sites'). For commercial roles, lead with quota attainment percentages, account growth, and any oncology or diagnostics-specific quota history.

recommended

For Shield commercial and primary-care sales roles, foreground primary-care sell

For Shield commercial and primary-care sales roles, foreground primary-care selling experience and screening-test launch experience. Shield's commercial model is materially different from oncology specialty selling because the call point is the primary-care physician and care team, the decision unit is broader (PCP, RN, MA, clinical staff), and the competitive landscape includes Cologuard and colonoscopy. Candidates with prior Cologuard, vaccine, or other primary-care screening-product experience are particularly attractive. Quantify call patterns (calls per day, account penetration, growth over baseline) explicitly.

recommended

For oncology specialty sales and Guardant360/Reveal roles, foreground oncology k

For oncology specialty sales and Guardant360/Reveal roles, foreground oncology key-account management. Community oncology and academic-medical-center selling differ from primary care in cycle length, decision unit (medical oncologists, pathologists, lab directors, P&T committees), and evidence-based selling expectations. Reference specific oncology programs you have launched or grown, NCCN-guideline-relevant clinical conversations you have led, and any health-system or integrated-delivery-network access wins.

recommended

For R&D, computational biology, and bioinformatics roles, frame yourself toward

For R&D, computational biology, and bioinformatics roles, frame yourself toward translational science rather than purely discovery. Guardant's R&D engine is heavily oriented toward clinically deployable assays — therefore, candidates with experience translating algorithms or wet-lab methods into validated, regulated tests have an advantage over candidates with only academic publications. Reference specific tools (for example, BWA, GATK, Mutect2, Strelka, scikit-learn, PyTorch), specific pipelines you have built or contributed to, and any CLIA-validated or 510(k)-supporting evidence packages you have authored or contributed to.

recommended

Use a single-column, ATS-friendly format

Use a single-column, ATS-friendly format. SmartRecruiters parses well-structured resumes reliably, but it stumbles on multi-column layouts, embedded text boxes, headers and footers with critical content, graphics-heavy designs, and non-standard section headings. Use 'Experience,' 'Education,' 'Skills,' 'Publications,' and 'Certifications' as section labels. Save as PDF unless the requisition specifies .docx. Avoid embedded images, scanned content, or unusual fonts that do not embed cleanly.

recommended

Be precise about geography and onsite expectations

Be precise about geography and onsite expectations. Most R&D, laboratory operations, and corporate-function roles are tied to Palo Alto or Redwood City and operate on a hybrid (typically 3+ days on-site) basis. Government affairs and select clinical/regulatory roles are based in Washington, D.C. Field-based sales roles cover defined geographic territories. If you are not local to a required hub and the requisition does not list relocation support, address your relocation plan directly in your cover letter — vague language about 'open to relocation' that is contradicted by your address often results in early rejection.

recommended

If you have biopharma research-services or pharmaceutical-partnership experience

If you have biopharma research-services or pharmaceutical-partnership experience, make it explicit. Guardant's biopharma business is a meaningful and growing part of revenue, providing genomic profiling and MRD services to drug developers across multiple oncology programs. Candidates with prior experience working on or with pharma alliance teams (for example, in companion diagnostic co-development, biomarker strategy, or clinical-trial enrollment support) are differentiated.

ATS System: SmartRecruiters

Guardant Health uses SmartRecruiters as its applicant tracking system. The job board is hosted at careers.smartrecruiters.com/GuardantHealth (the company's SmartRecruiters identifier is 'GuardantHealth' — case-sensitive). SmartRecruiters is a modern, structured-hiring ATS commonly used by mid-cap and later-stage biotechs, diagnostics, and tech-forward life sciences companies. It supports clean PDF and .docx parsing, configurable interview kits and scorecards, an integrated assessment framework, and a candidate-facing portal where you can view application status and saved jobs. Compared with legacy Taleo or older iCIMS instances, SmartRecruiters tends to produce a smoother applicant experience and a faster, more standardized internal evaluation. Field-based sales, primary-care commercial, and corporate roles all flow through the same SmartRecruiters instance regardless of geography or department.

Apply directly through careers.smartrecruiters.com/GuardantHealth or through the corporate careers page at guardanthealth.com/careers (which redirects to SmartRecruiters). Avoid third-party aggregators where possible — they sometimes rehost roles with stale links or expired requisition IDs.
SmartRecruiters parses PDF and .docx files reliably. Avoid scanned PDFs, image-based resumes, or PDFs with unusual fonts that do not embed cleanly into the file.
Fill in every field on the application form, including the optional ones. SmartRecruiters hiring teams configure custom screening questions intentionally, and partial responses can flag your application for lower-priority review.
If you withdraw and reapply later, SmartRecruiters retains your prior application history and recruiter notes. Avoid creating multiple accounts under different email addresses — this fragments your record and signals lack of organization to recruiters who notice it.
Once submitted, SmartRecruiters sends an automated confirmation. Genuine interview invitations come from a Guardant Health (@guardanthealth.com) email address or directly from the SmartRecruiters platform (smartrecruiters.com domain). Be alert for diagnostics- and oncology-themed phishing scams that have impersonated biotech recruiters in recent years.

Complete SmartRecruiters Resume Guide →

Interview Culture

Guardant Health's interview culture is best described as scientifically rigorous, mission-anchored, and increasingly process-disciplined as the company has scaled from a venture-backed clinical-stage diagnostics firm into a multi-product commercial-stage public company. Across functions, candidates report that the loop is designed to test whether you can do the actual work, whether you understand precision oncology at a level that lets you contribute substantively from week one, and whether you connect personally with the company's stated mission of conquering cancer with data. For R&D, computational biology, and laboratory roles, expect deep scientific scrutiny. Hiring managers at the senior scientist, principal scientist, and director level often hold PhDs from strong programs (Stanford, MIT, UCSF, Berkeley, Johns Hopkins, and similar) and they will probe both breadth (do you understand cell-free DNA biology, methylation, and MRD-platform trade-offs beyond your immediate work?) and depth (can you defend specific methods choices in your most recent project?). A common pattern is a 'present your past work' or journal-club session where you walk the panel through a recent project or paper and answer probing questions about methods, statistics, and clinical implications. The bar leans closer to academia than to legacy diagnostics: candidates with strong fundamentals, intellectual humility, and the ability to translate science into clinically deployable products do well. For CLIA laboratory operations, quality, and regulatory roles, the tone shifts toward execution rigor. Interviews emphasize CLIA and CAP compliance, deviation handling, change control, validation strategy, and the realities of running a high-throughput regulated lab where every result is a clinical decision. Expect behavioral questions framed around real situations — tell me about a time you had to escalate a CAPA on a deadline, walk me through a validation challenge you have led, how would you handle a proficiency-testing failure on a Guardant360 panel. Hiring managers want to know that you have lived these problems, not just read about them. For commercial, market access, and field-based medical roles, the loop emphasizes account knowledge, payer dynamics in liquid-biopsy and screening reimbursement, and the operational complexity of getting a Guardant test from a clinical decision through specimen logistics, lab processing, result delivery, and reimbursement. Account managers and sales leaders are expected to understand the call points (oncology specialty for Guardant360 and Reveal; primary care for Shield), the specific payer and Medicare landscape (national coverage determinations, local coverage determinations, prior authorization patterns), and the competitive context — particularly the head-to-head dynamics versus Natera Signatera in MRD and versus Exact Sciences Cologuard and colonoscopy in screening. For software engineering and product roles, the loop combines a coding interview, a system-design discussion (for senior engineers), and conversations focused on building software for a regulated diagnostics environment. Familiarity with HIPAA, SOC 2, validated software lifecycle practices, and the realities of integrating with electronic health records (Epic, Cerner, Athenahealth) is increasingly expected. Culturally, Guardant is in a multi-year transition from founder-led startup to scaled commercial-stage public company. The early years were defined by a small, scientifically obsessive group operating under the personal direction of co-founders Eltoukhy and Talasaz, with deep ties into the Stanford engineering and Bay Area biotech ecosystems. The post-Shield-approval phase has rapidly added commercial and operational talent from Roche/Genentech, Exact Sciences, Natera, Illumina, Foundation Medicine, and large-cap pharma, which has imported a more structured operating style. Candidates report a workplace that values intensity and ownership, particularly during launch surges and clinical-trial ramps, balanced against a leadership team that has been deliberate about building durable HR infrastructure rather than running on burnout. Dual-CEO leadership is a real and visible part of the culture. Eltoukhy and Talasaz are widely respected internally as deeply technical operators who remain engaged with science and product strategy. The dual-leadership structure does require Guardant employees to be comfortable with some ambiguity in decision rights at the top, and senior leaders are expected to navigate that nuance with maturity. Hybrid and remote arrangements exist but are role-dependent — laboratory, manufacturing, and most R&D roles are on-site by necessity, while commercial, product, IT, finance, and corporate roles are more flexible. Field-based sales roles are home-office-based with significant travel.

What Guardant Health Looks For

Precision oncology domain knowledge — cfDNA biology, MRD platform trade-offs (tumor-informed versus tumor-naive), companion diagnostic strategy, screening market dynamics, NCCN-guideline literacy. Guardant hires candidates who already speak the language; ramp time is short because the organization is in commercial execution mode against well-funded competitors.
Regulated-environment rigor for any role touching the lab or the product. CLIA, CAP, ISO 15189, FDA 21 CFR Part 820, 510(k) and PMA experience, and HIPAA literacy are baseline expectations for laboratory operations, R&D translation, regulatory affairs, quality, and clinical operations hires.
Operational execution under launch and scale pressure. Shield's 2024 FDA approval and the subsequent commercial mobilization have made operational excellence — sales-force productivity, lab throughput, payer access, evidence generation — a central organizational priority. Candidates who have lived through a commercial launch ramp and can talk credibly about scale-up are in high demand.
Comfort with intense competition. Guardant operates head-to-head against Natera in MRD and against Exact Sciences in colorectal screening, with Foundation Medicine, Veracyte, Caris, and Tempus AI in adjacent positions. Candidates who can articulate the competitive landscape clearly, without bravado and without naivety, signal the kind of strategic maturity Guardant prizes.
Mission alignment with the cancer-data thesis. The dual-CEO leadership has consistently framed Guardant's purpose as conquering cancer with data — using genomic, clinical, and longitudinal real-world evidence to move outcomes at population scale. Candidates who connect personally with that mission, beyond the commercial opportunity, tend to find more durable engagement at Guardant.
Pipeline curiosity and platform thinking. Beyond the three commercial products, Guardant continues to invest in next-generation assays, biopharma data partnerships, AI- and machine-learning-enabled interpretation, and international expansion (notably the Japan subsidiary). Candidates who can speak to where liquid biopsy is heading — multi-cancer early detection, integration with imaging, real-world evidence at population scale — signal that they are joining for the trajectory, not just the current portfolio.
Cross-functional fluency. Guardant's commercial, R&D, regulatory, and lab organizations are tightly interlocked because the product is the assay, and the assay only generates value through a clinically integrated workflow. Candidates with prior experience operating across the wet-lab/dry-lab/commercial seams of a diagnostics business have a measurable edge.

Frequently Asked Questions

Who runs Guardant Health and what is the dual-CEO structure?

Guardant Health is led by co-Chief Executive Officers Helmy Eltoukhy, PhD and AmirAli Talasaz, PhD, who co-founded the company in 2012 and have served as co-CEOs and co-Chairs of the Board ever since. Both are Stanford-trained engineers from the early next-generation sequencing world. The dual-CEO structure is unusual at scale and has been deliberately maintained — the two have publicly described their working relationship as a long-standing partnership in which they divide functional oversight and major strategic decisions are made jointly. For employees, this means that decision rights at the very top are shared in ways that require some maturity to navigate, but it has not produced the dysfunction that critics of dual-CEO models sometimes predict. The model is part of how Guardant has built its identity and is a feature candidates should understand rather than be surprised by.

What is the difference between Guardant360, Reveal, and Shield?

These are three distinct products addressing three different points in the cancer care continuum. Guardant360 is a comprehensive genomic profiling assay used in advanced solid tumors to help oncologists pick targeted therapies and immunotherapies — it received FDA approval as a companion diagnostic in 2020 and is the company's revenue base. Reveal is a tumor-naive, methylation-based molecular residual disease (MRD) test used after definitive treatment to detect residual or recurrent cancer at a molecular level before imaging would show it; it competes most directly with Natera's Signatera. Shield is a blood-based colorectal cancer screening test for average-risk adults age 45 and older — it received FDA premarket approval in July 2024 (the first such blood test ever approved) and competes in the population screening market against Cologuard and colonoscopy. Each product has its own commercial channel, evidence pipeline, and regulatory trajectory.

How significant is the Shield FDA approval?

It is the most consequential commercial event in the company's history to date. Colorectal cancer screening in the U.S. is a multibillion-dollar annual market, and roughly one-third of eligible Americans are not up to date on screening. A blood test that can be ordered during a routine primary-care visit is operationally easier than scheduling a colonoscopy or completing an at-home stool test, which is the strategic premise behind Shield. The July 2024 FDA premarket approval also unlocked Medicare national coverage and accelerated commercial payer coverage discussions, which in turn supported a substantial sales-force build-out in 2024 and 2025. Whether Shield ultimately delivers on the multi-hundred-million-dollar to multi-billion-dollar revenue opportunity will depend on guideline inclusion, primary-care adoption, and competitive response from Exact Sciences and others — but the approval itself was a transformative regulatory milestone.

Who are Guardant Health's main competitors?

The competitive landscape varies by product. In molecular residual disease, Natera (NASDAQ: NTRA) is the principal competitor through its Signatera assay, which is tumor-informed and has substantial commercial momentum in colorectal and other tumor types. In colorectal cancer screening, Exact Sciences (NASDAQ: EXAS) is the dominant incumbent through Cologuard and is developing a next-generation Cologuard Plus product, alongside the long-standing colonoscopy standard of care. In comprehensive genomic profiling for therapy selection, Foundation Medicine (a Roche subsidiary), Caris Life Sciences, and Tempus AI all compete with Guardant360. Veracyte competes in select tumor types with its tissue-based and emerging blood-based assays. The competitive environment is intense and well-funded, which materially shapes Guardant's hiring priorities and operational tempo.

What ATS does Guardant Health use?

Guardant Health uses SmartRecruiters, hosted at careers.smartrecruiters.com/GuardantHealth (the SmartRecruiters identifier 'GuardantHealth' is case-sensitive). SmartRecruiters is a modern, structured-hiring ATS that supports clean PDF and .docx parsing, configurable interview kits, scorecards, integrated assessments, and a candidate-facing portal where you can track application status and saved jobs. The company careers page at guardanthealth.com/careers redirects to the SmartRecruiters job board. Most professional, scientific, commercial, and corporate roles are routed through SmartRecruiters; field-based sales requisitions for Shield's commercial expansion are also posted there.

Where is Guardant Health hiring most aggressively right now?

As of early 2026, three concentrations stand out. First, Shield commercial sales — primary-care territory representatives, district managers, and supporting commercial operations roles to extend coverage of the U.S. primary-care call point in support of the Shield colorectal screening launch. Second, oncology specialty sales for Guardant360 and Reveal, particularly to support continued growth in MRD and to defend competitively against Natera Signatera. Third, R&D, computational biology, and laboratory operations in Palo Alto and Redwood City, supporting both the existing product portfolio and pipeline expansion. Regulatory affairs, medical affairs, software engineering (data platform, EHR integrations, payer-facing tools), and select corporate functions also hire continuously.

Does Guardant Health sponsor work visas?

Guardant selectively sponsors work visas, primarily for advanced scientific, computational biology, and software engineering roles where candidates have specialized expertise that is difficult to source domestically. H-1B sponsorship is more common for senior scientist, computational biology, and machine-learning roles, and for select regulatory affairs positions. Most field-based sales roles, primary-care commercial roles, laboratory technician roles, and entry-to-mid-level corporate functions are typically restricted to candidates who already hold U.S. work authorization without sponsorship. The application form will ask about sponsorship status; answer honestly, because visa-related misrepresentation discovered later in the process is grounds for offer rescission or termination.

How long does the hiring process take?

End-to-end timelines vary by function. Field-based sales territory roles, particularly during the active Shield commercial mobilization, can move from application to offer in 3 to 5 weeks. Most professional and individual contributor roles run 5 to 9 weeks. Director and above hires often run 9 to 14 weeks because of additional executive interviews, broader stakeholder consensus, and competing priorities at the leadership level. Add another 1 to 3 weeks for background check, offer negotiation, and start date scheduling. Roles requiring relocation or visa sponsorship can extend total timelines further.

What does compensation look like at Guardant Health?

Compensation is competitive with Bay Area biotech and diagnostics peers and is anchored in a base salary, target bonus or sales incentive plan, restricted stock unit (RSU) grant, and benefits package. Bonus targets typically range from 10% at individual contributor levels to 20-30% at director level and higher at senior leadership; sales roles operate on incentive plans tied to territory and corporate performance. Equity is granted as RSUs tied to NASDAQ-listed GH stock, with multi-year vesting (commonly 4-year vesting with a 1-year cliff). Sign-on bonuses are routine for candidates leaving competing offers and for relocations. Negotiation is accepted; recruiters expect a reasonable counter and most offers have headroom on equity and sign-on, less on base.

Is Guardant Health profitable, and should that affect my decision to join?

Guardant Health is not yet GAAP-profitable on a sustained basis. The company is investing meaningfully in Shield commercialization, MRD trial generation, evidence packages for payer coverage, and continued pipeline development, and free cash flow remains a closely watched metric on quarterly earnings calls. The company has financed itself through public equity, convertible notes, and operating revenue. For a candidate, the practical question is whether Guardant's path to durable cash generation looks credible — and most analysts and operators believe the combination of Guardant360 base revenue, growing MRD adoption, and Shield's screening upside provides a credible runway. Equity grants tied to GH stock will move with how the market judges that runway, which is part of the trade-off any pre-profitability commercial-stage biotech presents to its employees.

Open Positions

Guardant Health currently has 11 open positions.

Check Your Resume Before Applying → View 11 open positions at Guardant Health

Related Resources

Similar Companies

Sources

Guardant Health — Careers — Guardant Health, Inc.
Guardant Health Job Board (SmartRecruiters) — SmartRecruiters / Guardant Health
Guardant Health — Corporate Overview — Guardant Health, Inc.
U.S. FDA — Approval of Shield Blood Test for Colorectal Cancer Screening (July 2024) — U.S. Food and Drug Administration
Guardant Health — SEC Filings (Form 10-K) — U.S. Securities and Exchange Commission
Guardant360 Product Information — Guardant Health, Inc.
Guardant Reveal MRD Assay — Guardant Health, Inc.
Shield Blood Test for Colorectal Cancer Screening — Guardant Health, Inc.